Biochemically Recurrent Prostate Cancer

Olaparib monotherapy may be an effective treatment option for certain men with biochemically recurrent prostate cancer, according to results of a nonrandomized phase 2 trial.

In this video, Stephen Freedland, MD, discusses the results of the EMBARK study into high-risk, nonmetastatic biochemically recurrent prostate cancer, which he co-presented at ASCO Annual Meeting.